<DOC>
	<DOCNO>NCT00914823</DOCNO>
	<brief_summary>The investigator seek participant study role kisspeptin reproductive system . Kisspeptin naturally occur hormone human stimulate production reproductive hormone . The investigator hypothesize kisspeptin administration useful tool characterize certain reproductive disorder .</brief_summary>
	<brief_title>Administration Kisspeptin Subjects With Reproductive Disorders</brief_title>
	<detailed_description>The master reproductive hormone GnRH ( gonadotropin-releasing hormone ) essential normal reproductive function . People hypogonadotropic hypogonadism ( IHH ) , hyperprolactinemia , polycystic ovarian syndrome ( PCOS ) secrete respond GnRH normal way . In study , investigator give participant , kisspeptinâ€” hormone naturally find human body know powerful stimulus GnRH secretion . They may also give participant GnRH determine participant able fully respond kisspeptin . The goal study use kisspeptin administration probe condition GnRH neuron people various reproductive disorder well understand underlie reason disorder . Investigators hope gain new insight GnRH neuronal function ( dysfunction ) lead good diagnostics future . The investigator seek men woman hypogonadotropic hypogonadism ( HH ) hyperprolactinemia , well woman PCOS . Study participation involve 1 2 outpatient visit 1 2 , 3-15-hour hospital admission ( ) participant receive kisspeptin and/or gonadotropin-releasing hormone ( GnRH ) intravenous line ( IV ) . Remuneration $ 800 study completion . Individuals interested learning may email MGHKisspeptinResearch @ partners.org call 617-726-5383 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hyperprolactinemia</mesh_term>
	<mesh_term>Kallmann Syndrome</mesh_term>
	<criteria>All subject reproductive disorder meet follow criterion : History : 18 year old , medical condition stable well control , prescription medication know affect reproductive endocrine function least 2 month 5 halflives drug ( whichever short ) except medication use treat subject 's reproductive condition , history medication reaction require emergency medical care , illicit drug use , excessive alcohol consumption ( &lt; 10 drinks/week ) , currently seek fertility , woman , breastfeed pregnant , applicable , able undergo appropriate washout hormone therapy . Physical Examination : normal blood pressure , ( systolic BP &lt; 140 mm Hg , diastolic &lt; 90 mm Hg ) . Laboratory Studies : white blood cell , platelet count , TSH 90 % low limit 110 % upper limit reference range , prolactin 110 % upper limit reference range exception participant hyperprolactinemia definition elevate level prolactin . hemoglobin 1. woman : le 0.5 gm/dL low limit reference range normal woman , 2. men : i. adequate testosterone replacement therapy : normal male reference range , ii.off testosterone replacement therapy : low 0.5 gm/dL low limit reference range normal woman ( &gt; 11.5 gm/dL laboratory ) , men hypogonadism treatment low serum testosterone level cause hemoglobin concentration fall female range , BUN , creatinine , AST , ALT elevate , woman , negative serum hCG pregnancy test time screening ( additional urine pregnancy test conduct prior drug administration ) . Additional criterion base subject population : 1 . Men woman hypogonadotropic hypogonadism : All subject confirm diagnosis low sex steroid set low inappropriately normal gonadotropin . If need verify clinical criterion , additional diagnostic lab image test may perform include limited ferritin , prolactin , sex steroid , FSH , LH brain MRI . 2 . Women Polycystic Ovarian Syndrome ( PCOS ) : All subject confirm diagnosis PCOS evidence 2 following : oligoamenorrhea , clinical biochemical hyperandrogenism , polycystic ovarian morphology , exclusion identifiable condition would result pattern . If need verify clinical criterion , additional diagnostic lab may draw include limited 17OHP , sex steroid , FSH , LH . 3 . Men woman hyperprolactinemia : All subject confirm diagnosis elevate level prolactin measure via blood test MRI image confirm pituitary abnormality microprolactinoma ( &lt; 10 mm ) . Patients macroprolactinoma exclude . We enroll subject first present hyperprolactinemia prior receive medication subject treat dopamine agonist bromocriptine . We ask subject treat bromocriptine complete washout period prior kisspeptin administration visit ( ) . The washout period last least 2 week . We perform blood test prior kisspeptin administration visit ( ) confirm elevate level prolactin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>